<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1635">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139875</url>
  </required_header>
  <id_info>
    <org_study_id>MTU-EC-OT-1-266/64</org_study_id>
    <nct_id>NCT05139875</nct_id>
  </id_info>
  <brief_title>Comparing Intra-articular Betamethasone (Diprospan) and Triamcinolone Acetonide Injection in Knee Osteoarthritis</brief_title>
  <official_title>A Comparative Study of Betamethasone (Diprospan) and Triamcinolone Acetonide as Single Intra-Articular Injection in Knee Osteoarthritis, A Double-Blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of Intra-articular corticosteroid&#xD;
      injection between Betamethasone (Diprospan) and Triamcinolone acetonide for treatment of knee&#xD;
      osteoarthritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients giving written&#xD;
      informed consent will be chosen for eligibility for the study entry. At day 0 (before&#xD;
      intra-articular injection), patients who meet the eligibility criteria will be randomized in&#xD;
      a double-blind manner (participant and investigator) in a 1:1 ratio to Betamethasone&#xD;
      (Diprospan 1 ml) or Triamcinolone acetonide (40 mg) single intra-articular injection&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized and assigned to betamethasone (Diprospan) group or Triamcinolone acetonide group in parallel for the duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant and Care Provider will not know which drug is injected to the investigated knee because the opaque syringe is used to inject.&#xD;
Investigator and outcomes assessor will not known the group of participants because randomization, they only know the number of the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of 100-mm Visual analog scale (VAS) Pain Score between Betamethasone (Diprospan) and Triamcinolone group</measure>
    <time_frame>Baseline before intra-articular injection, 1 day, 2 days, 3 days, 1 week, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months after the day of intra-articular injection</time_frame>
    <description>The 100-mm VAS pain score is a self-reported instrument assessing Pain Score at 1 day, 2 days, 3 days, 1 week, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months after the day of intra-articular injection&#xD;
Participants will assess the VAS pain score at rest and on-movement&#xD;
VAS Pain at rest is evaluated when the participant's wakeup in the morning&#xD;
VAS Pain on-movement is evaluated when the participant's walking for 10 meters and then resting for 5 minutes&#xD;
Possible scores range from 0 (no pain) to 100 (worst imaginable pain)&#xD;
Higher scores mean a worse pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of Modified Western Ontario and McMaster Universities Arthritis Index (WOMAC) score between Betamethasone (Diprospan) and Triamcinolone group</measure>
    <time_frame>Baseline before intra-articular injection,1 month, 3 months, 6 months after intra-articular injection</time_frame>
    <description>The Modified WOMAC score is a validated, self-reported instrument consisting of 24 items divided into 3 subscales (Pain, Stiffness, Physical function).&#xD;
The test questions are scored on a scale of 0-4, which corresponds to None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).&#xD;
Possible scores range from 0-20 for pain, 0-8 for Stiffness, 0-68 for Physical function.&#xD;
a sum of the scores for all three subscales gives a total WOMAC score (0-96)&#xD;
Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of University of California and Los Angeles (UCLA) score between Betamethasone (Diprospan) and Triamcinolone group</measure>
    <time_frame>Baseline before intra-articular injection,1 month, 3 months, 6 months after intra-articular injection</time_frame>
    <description>The UCLA is a 10-point scale measurement that evaluates patients' daily activity levels.&#xD;
The 10-point scale is leveled from 1 to 10 (1= worst, 10 = best).&#xD;
Level 1 is wholly inactive and dependent on others, while level 6 is unlimited housework and shopping and level 10 is regular participation in impact sports, such as jogging or tennis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Range of motion between Betamethasone (Diprospan) and Triamcinolone group</measure>
    <time_frame>Baseline before intra-articular injection,1 month, 3 months, 6 months after intra-articular injection</time_frame>
    <description>- Flexion and extension angle of the knee is measured by a long-arm goniometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Time up-and-go test between Betamethasone (Diprospan) and Triamcinolone group</measure>
    <time_frame>Baseline before intra-articular injection,1 month, 3 months, 6 months after intra-articular injection</time_frame>
    <description>The Time up-and-go test (TUGT) measures the time (seconds) that the patient takes to rise from a chair and walk for 3 meters. Then, he or she turns around and comes back to the seat at the initial position.&#xD;
They were permitted to use walking aids if they wished.&#xD;
TUGT was a reliable and valid test for quantifying functional mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of 2-minutes walking test between Betamethasone (Diprospan) and Triamcinolone group</measure>
    <time_frame>Baseline before intra-articular injection,1 month, 3 months, 6 months after intra-articular injection</time_frame>
    <description>Participants were instructed to walk for 2 minutes at their normal pace up and down a designated corridor, turning around at each end of the corridor without stopping&#xD;
They were permitted to use walking aids if they wished.&#xD;
The results were recorded as the total distance walked in meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects of intra-articular steroid injection</measure>
    <time_frame>1 month, 3 months, 6 months after intra-articular injection</time_frame>
    <description>Injection site reaction, Erythema, Swelling, Injection-site pain, Pruritus, cellulitis were observed after intra-articular injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of Total Paracetamol and Tramadol used between Betamethasone (Diprospan) and Triamcinolone group</measure>
    <time_frame>6 months after intra-articular injection</time_frame>
    <description>Post-injection protocol, Participants can use Paracetamol 500 mg 2 tabs every 4 hours for knee pain if it did not relieve the pain they can take Tramadol 50 mg 1 cap every 6 hours.&#xD;
The total use of Paracetamol and Tramadol was recorded. (tablet)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Betamethasone (Diprospan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant received single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate 1 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant received single intra-articular Triamcinolone acetonide 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone Dipropionate / Betamethasone Sodium Phosphate</intervention_name>
    <description>Single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate (Diprospan) injections to affected knee</description>
    <arm_group_label>Betamethasone (Diprospan)</arm_group_label>
    <other_name>Diprospan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide 40mg/mL</intervention_name>
    <description>Single intra-articular Triamcinolone Acetonide injections to affected knee</description>
    <arm_group_label>Triamcinolone acetonide</arm_group_label>
    <other_name>Kanolone-F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic Primary knee osteoarthritis (Kellgren-Lawrence stage 2 or 3)&#xD;
&#xD;
          2. Failed other conservative treatment&#xD;
&#xD;
          3. Comply with protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to any of the medications in this protocol (Betamethasone, Triamcinolone,&#xD;
             Paracetamol, Tramadol)&#xD;
&#xD;
          2. Previous fracture or surgical procedure&#xD;
&#xD;
          3. Previous intra-articular injection in the past 6 months&#xD;
&#xD;
          4. Previous oral Symptomatic slow-acting drugs for osteoarthritis (SYSADOA) (Glucosamine,&#xD;
             Diacerein) used in the past 6 months&#xD;
&#xD;
          5. Current infection in the affected limb&#xD;
&#xD;
          6. Uncontrolled Diabetes Mellitus&#xD;
&#xD;
          7. Primary or secondary adrenal insufficiency&#xD;
&#xD;
          8. Coagulopathy or current anticoagulant used&#xD;
&#xD;
          9. Current steroid used&#xD;
&#xD;
         10. Lower extremity weakness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KITTIPONG WATTANASIRISOMBAT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Thammasat University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KITTIPONG WATTANASIRISOMBAT, MD</last_name>
    <phone>+66899498582</phone>
    <email>kittipong43705@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Khlong Luang</city>
        <state>Pathumthani</state>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Kittipong Wattanasirisombat, MD</last_name>
      <phone>0899498582</phone>
      <email>kittipong43705@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Piya Pinsornsak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krit Boontanapibul, Asst. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA. 2021 Feb 9;325(6):568-578. doi: 10.1001/jama.2020.22171. Review.</citation>
    <PMID>33560326</PMID>
  </reference>
  <reference>
    <citation>Uson J, Rodriguez-García SC, Castellanos-Moreira R, O'Neill TW, Doherty M, Boesen M, Pandit H, Möller Parera I, Vardanyan V, Terslev L, Kampen WU, D'Agostino MA, Berenbaum F, Nikiphorou E, Pitsillidou IA, de la Torre-Aboki J, Carmona L, Naredo E. EULAR recommendations for intra-articular therapies. Ann Rheum Dis. 2021 Oct;80(10):1299-1305. doi: 10.1136/annrheumdis-2021-220266. Epub 2021 May 25.</citation>
    <PMID>34035002</PMID>
  </reference>
  <reference>
    <citation>Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589. doi: 10.1016/j.joca.2019.06.011. Epub 2019 Jul 3. Review.</citation>
    <PMID>31278997</PMID>
  </reference>
  <reference>
    <citation>Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E, Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD, DiRenzo D, Fontanarosa J, Giradi G, Ishimori M, Misra D, Shah AA, Shmagel AK, Thoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020 Feb;72(2):220-233. doi: 10.1002/art.41142. Epub 2020 Jan 6. Erratum in: Arthritis Rheumatol. 2021 May;73(5):799.</citation>
    <PMID>31908163</PMID>
  </reference>
  <reference>
    <citation>Jevsevar DS, Brown GA, Jones DL, Matzkin EG, Manner PA, Mooar P, Schousboe JT, Stovitz S, Sanders JO, Bozic KJ, Goldberg MJ, Martin WR 3rd, Cummins DS, Donnelly P, Woznica A, Gross L; American Academy of Orthopaedic Surgeons. The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition. J Bone Joint Surg Am. 2013 Oct 16;95(20):1885-6.</citation>
    <PMID>24288804</PMID>
  </reference>
  <reference>
    <citation>Oo WM, Liu X, Hunter DJ. Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis. Expert Opin Drug Metab Toxicol. 2019 Dec;15(12):1021-1032. doi: 10.1080/17425255.2019.1691997. Epub 2019 Nov 13. Review.</citation>
    <PMID>31709838</PMID>
  </reference>
  <reference>
    <citation>Garg N, Perry L, Deodhar A. Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids. Clin Rheumatol. 2014 Dec;33(12):1695-706. doi: 10.1007/s10067-014-2572-8. Epub 2014 Mar 21. Review.</citation>
    <PMID>24651914</PMID>
  </reference>
  <results_reference>
    <citation>Douglas RJ. Corticosteroid injection into the osteoarthritic knee: drug selection, dose, and injection frequency. Int J Clin Pract. 2012 Jul;66(7):699-704. doi: 10.1111/j.1742-1241.2012.02963.x. Review.</citation>
    <PMID>22698422</PMID>
  </results_reference>
  <results_reference>
    <citation>Cole BJ, Schumacher HR Jr. Injectable corticosteroids in modern practice. J Am Acad Orthop Surg. 2005 Jan-Feb;13(1):37-46. Review.</citation>
    <PMID>15712981</PMID>
  </results_reference>
  <results_reference>
    <citation>Schumacher HR, Chen LX. Injectable corticosteroids in treatment of arthritis of the knee. Am J Med. 2005 Nov;118(11):1208-14. Review.</citation>
    <PMID>16271901</PMID>
  </results_reference>
  <results_reference>
    <citation>Husby G, Kåss E, Spongsveen KL. Comparative double-blind trial of intra-articular injections of two long-acting forms of betamethasone. Scand J Rheumatol. 1975;4(3):118-20.</citation>
    <PMID>1101375</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30. doi: 10.1186/1710-1492-9-30.</citation>
    <PMID>23947590</PMID>
  </results_reference>
  <results_reference>
    <citation>Yavuz U, Sökücü S, Albayrak A, Oztürk K. Efficacy comparisons of the intraarticular steroidal agents in the patients with knee osteoarthritis. Rheumatol Int. 2012 Nov;32(11):3391-6. doi: 10.1007/s00296-011-2188-0. Epub 2011 Nov 5.</citation>
    <PMID>22057944</PMID>
  </results_reference>
  <results_reference>
    <citation>Wollstein R, Chaimsky G, Carlson L, Watson HK, Wollstein G, Saleh J. Evaluating short-term pain after steroid injection. Am J Orthop (Belle Mead NJ). 2007 Mar;36(3):128-31.</citation>
    <PMID>17461394</PMID>
  </results_reference>
  <results_reference>
    <citation>Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J. 2001 May;18(3):205-7.</citation>
    <PMID>11354213</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuptniratsaikul V, Rattanachaiyanont M. Validation of a modified Thai version of the Western Ontario and McMaster (WOMAC) osteoarthritis index for knee osteoarthritis. Clin Rheumatol. 2007 Oct;26(10):1641-5. Epub 2007 Feb 20.</citation>
    <PMID>17310271</PMID>
  </results_reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thammasat University</investigator_affiliation>
    <investigator_full_name>Kittipong Wattanasirisombat</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Intra-articular injections</keyword>
  <keyword>Corticosteroids</keyword>
  <keyword>Triamcinolone acetonide</keyword>
  <keyword>Betamethasone</keyword>
  <keyword>Nonoperative management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal.&#xD;
To achieve aims in the approved proposal.&#xD;
Proposals should be directed to kittipong43705@gmail.com.&#xD;
To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

